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RNA Helicase Signaling Is Critical for Type I Interferon Production
and Protection against Rift Valley Fever Virus during Mucosal
Challenge
Megan E. Ermler,a,b Ekaterina Yerukhim,a Jill Schriewer,c Stefan Schattgen,d Zachary Traylor,a Adam R. Wespiser,d Daniel R. Caffrey,d
Zhijian J. Chen,e Charles H. King,a Michael Gale, Jr.,f Marco Colonna,g Katherine A. Fitzgerald,d R. Mark L. Buller,c Amy G. Hisea,b
Center for Global Health and Diseases, Case Western Reserve University, Cleveland, Ohio, USAa; Department of Pathology, Case Western Reserve University, Cleveland,
Ohio, USAb; Department of Molecular Microbiology and Immunology, Saint Louis University School of Medicine, St. Louis, Missouri, USAc; Division of Infectious Diseases
and Immunology, University of Massachusetts Medical School, Worcester, Massachusetts, USAd; Department of Molecular Biology, UT Southwestern Medical Center,
Dallas, Texas, USAe; Department of Immunology, University of Washington School of Medicine, Seattle, Washington, USAf; Department of Pathology and Immunology,
Washington University School of Medicine, St. Louis, Missouri, USAg
Rift Valley fever virus (RVFV) is an emerging RNA virus with devastating economic and social consequences. Clinically, RVFV
induces a gamut of symptoms ranging from febrile illness to retinitis, hepatic necrosis, hemorrhagic fever, and death. It is known
that type I interferon (IFN) responses can be protective against severe pathology; however, it is unknown which innate immune
receptor pathways are crucial for mounting this response. Using both in vitro assays and in vivomucosal mouse challenge, we
demonstrate here that RNA helicases are critical for IFN production by immune cells and that signaling through the helicase
adaptor molecule MAVS (mitochondrial antiviral signaling) is protective against mortality andmore subtle pathology during
RVFV infection. In addition, we demonstrate that Toll-like-receptor-mediated signaling is not involved in IFN production, fur-
ther emphasizing the importance of the RNA cellular helicases in type I IFN responses to RVFV.
Rift Valley fever virus (RVFV) is a negative-strand RNA virus ofthe genus Phlebovirus (family Bunyaviridae) (1). Recurrent
outbreaks of Rift Valley fever virus have been documented
throughout Africa, with first reports in Kenya in 1930 (2). Re-
cently, the virus was established outside of continental Africa in
Madagascar (3) and the Arabian Peninsula (4). RVFV is virulent
in young livestock and induces spontaneous abortion in pregnant
animals. In humans, infection results in febrile illness and a subset
of patients experience retinitis, hepatitis, encephalitis, hemor-
rhagic fever, or death.High case fatality rates were reported for the
2006-2008 outbreaks in several countries for patients presenting
with severe symptoms suggestive of RVFV (5).
Although it is unknown which host factors determine whether
anRVFV-infected patient experiencesmild or severe diseaseman-
ifestations, it is known that type I interferon (IFN) responses can
be protective. Administration of the type I IFN inducer poly(I·C)
stabilized with polylysine and carboxymethyl cellulose was shown
to protect rodents frommortality associated with RVFV infection
(6). More directly, type I IFN has been shown to guard against
pathology when recombinant or human-derived alpha IFN
(IFN-) was administered to rhesus macaques prior to, or shortly
after, challenge with virulent RVFV (7). In addition, mice lacking
type I IFN receptor (IFNAR) were more susceptible to clinical
isolate and lab-attenuated strains of RVFV than wild-type (WT)
mice (8).
The innate immune receptors that recognize RVFV and induce
a signaling cascade leading to type I IFN production have not been
well characterized. Major classes of innate pattern recognition re-
ceptors (PRRs) include C-type lectin receptors (CLRs), Toll-like
receptors (TLRs), Nod-like receptors (NLRs), and retinoic acid-
inducible gene I (RIG-I)-like receptors (RLRs), also known as cel-
lular RNA helicases. These classic PRRs recognize pathogen-asso-
ciated molecular patterns (PAMPs) and initiate signaling that can
lead to an inflammatory or viral replication-interfering state
within the host (9). Transmembrane-bound CLRs recognize car-
bohydrate patterns and can be utilized for viral entry or can reg-
ulate IFN responses during viral infection (10–12). The NLR fam-
ily includes more than 20 proteins in humans. Recent work has
demonstrated that NLR member NOD2 is capable of recognizing
single-strand RNA (ssRNA) viral genomes and can initiate IFN
signaling through the adaptor molecule MAVS (mitochondrial
antiviral signaling; also known as IFNpromoter stimulator 1 [IPS-
1], CARD adaptor-inducing IFN- [Cardif], and virus-induced
signaling adaptor [VISA]) (13). In addition, many inflam-
masomes can be activated by viral nucleic acid (14–17).
Endosomal TLRs (TLR3, TLR7/8, TLR9) recognize nucleic ac-
ids and target recognition of intracellular pathogens, such as vi-
ruses (9). TLR3 recognizes viral genomic double-stranded RNA
(dsRNA) or replication intermediates and the synthetic dsRNA
ligand poly(I·C) (9). TLR7 and human TLR8 recognize viral ss-
RNA (18). In contrast, murine TLR8 does not recognize ssRNA
motifs and was originally thought to be nonfunctional; however,
subsequent work has shown that stimulation of murine TLR8 and
downstream NF-B activation can be achieved with immune re-
sponse modifiers used in combination with poly(T) oligodeoxy-
nucleotide (19). The potential role for TLR8 recognition of vac-
cinia virus and its DNA genome is under debate (20, 21). Because
RVFV is a negative sense ssRNAvirus, TLR3, TLR7, or TLR8 could
likely contribute to recognition and antiviral signaling.
Intracellular cytoplasmic DExD/H box helicase family mem-
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bers, including RIG-I, melanoma differentiation-associated gene
5 (MDA5), and Laboratory of Genetics and Physiology 2 (LGP2)
(22), can also sense viral PAMPs. RIG-I recognizes shorter blunt-
end dsRNA intermediates (23) with a 5=-triphosphatemoiety (24)
that are detected during viral replication of negative strand RNA
viruses. MDA5 induces IFN- production in response to the syn-
thetic dsRNA ligand poly(I·C) and to picornaviruses (25). It was
generally assumed thatMDA5 recognized longer dsRNA interme-
diates, although further analysis suggests that more complex
structures, such as branched RNA, may be needed to initiate re-
sponses (26). Both RIG-I and MDA5 have two caspase activation
and recruitment domains (CARD) (27) and signal through the
adaptormoleculeMAVS to induceNF-B and IFN signaling (28).
Although LGP2 lacks a CARD signaling motif, it has been shown
to be required for RIG-I and MDA5 antiviral signaling (29) in
contrast to a previous report suggesting that it may have function
as a negative regulator (30).
Previous studies using RVFV clone 13 (a naturally attenuated
strain lacking most of the NSs gene) demonstrated that short-
hairpin RNA (shRNA) targeting RIG-I abrogated IFN- pro-
moter activation inHEK (human embryonic kidney) 293T cells in
response to isolated RVFV RNA, whereas shRNA targeting of
MDA5 did not hinder IFN responses (31). In addition, treatment
of isolated clone 13 RNAwith shrimp alkaline phosphatase greatly
reduced IFN- stimulation (31), suggesting that the 5=-triphos-
phate moiety was responsible for activation through RIG-I. These
studies were an important first look into innate recognition of
RVFV; however, interpretation of these studies is limited as HEK
cells lack expression of TLR familymembers that potentially could
contribute to antiviral responses (32–34). It is likely that innate
immune cells, such as dendritic cells andmacrophages, will be the
major sources of IFNduring active RVFV infection, and these cells
could potentially recognize and respond to RVFV using different
receptor pathways than nonimmune cells. In the present study, we
investigated the role of RLR and TLR signaling in the induction of
IFN responses to RVFV, and the role that these innate pathways
play in protection from mucosal challenge with RVFV.
MATERIALS AND METHODS
Mice. C57BL/6 mice were purchased from Jackson Laboratories. Mice
deficient in TLR3, MyD88, and TRIF were generated by Shizuo Akira
(OsakaUniversity, Osaka, Japan). RIG-I knockoutmice were provided by
Michael Gale, Jr. (University ofWashington). MDA5-deficient mice were
provided by Marco Colonna (Washington University). MAVS-deficient
mice were generated by ZhijianChen (University of Texas Southwestern).
Wild-type controls from the same generation were used in MAVS animal
experiments, since this mouse strain is not fully backcrossed onto
C57BL/6. Mice were maintained in filter-top microisolator cages in ven-
tilated racks. Animal experiments were carried out under conditions ap-
proved by the Institutional Animal Care and Use Committee at Case
Western Reserve University and Saint Louis University.
Cells, viruses, and reagents. Attenuated RVFV strains rMP-12 and
NSs del were a gift from Shinji Makino (University of Texas Medical
Branch, Galveston, TX). RVFV rMP-12 strain (recovered from cells using
reverse genetics and containing a XhoI site) was derived from the MP-12
strain, initially made by passaging patient isolate ZH548 12 times in the
presence of 5-fluorouracil (35). The NSs del strain was derived from
rMP-12 and lacks virulence factor NSs (36). These samples were handled
under biosafety level 2 conditions unless previously inactivated. Samples
containing virus were inactivated by cross-linking RNA with 2 J of UV
light (Stratagene).
Immune cells were derived from the bone marrow of wild-type and
knockout mice using standard protocols (37, 38). For generation of con-
ventional dendritic cells (cDCs), bone marrow was isolated from femurs
and tibias and was cultured in DCmedia composed of RPMI 1640 media
with L-glutamine, 10% fetal bovine serum (FBS) (Atlanta Biologicals), 50
M 2-mercaptoethanol (Sigma-Aldrich), 10 mM sodium pyruvate, 10
mM penicillin-streptomycin, and 1/30 total volume addition of J558L
supernatant that contains granulocyte-macrophage colony-stimulating
factor (GM-CSF) (39). Cells were supplemented on days 3 and 6 with a
half volume of fresh medium and J558L supernatant. Semiadherent cells
were harvested between days 8 to 10. More than 80% of the cDC popula-
tion was CD11b and CD11c as determined by fluorescence-activated
cell sorting (FACS) analysis. To generate mixed plasmacytoid dendritic
cells (pDCs) and cDCs, DC media was used with the addition of 1 g of
FLT-3 ligand fusion protein (Bioexpress)/ml. Cells were fed on days 3 and
6 and were collected for use between days 8 to 10. The percent pDC/cDC
populationswere evaluated by FACS analysis. Bonemarrow-derivedmac-
rophages (BMDMs) were generated by culturing total bone marrow in
high glucose Dulbecco modified Eagle medium (DMEM) supplemented
with 10% FBS, 10 mMpenicillin-streptomycin, 10 mM sodium pyruvate,
10 mM HEPES, 50 M 2-mercaptoethanol, with 20% L929 cell condi-
tioned supernatant containing macrophage colony-stimulating factor
(M-CSF). Cells were cultured for 5 days, after which the media and non-
adherent cells were removed, and freshmedia were added every other day
until harvest between days 7 and 10. Typically, BMDMs were95% pos-
itive for CD11b and F4/80 as determined by FACS analysis. Differentiated
cells were counted, plated, and stimulated at 105 cells in 200 l (total
volume) per well in a 96-well plate. For infection studies with multiple
MOI of virus, cells were stimulated with media only control, poly(I·C)
(Imgenex), Pam3Cysk4 (InvivoGen), 5= triphosphate RNA (InvivoGen),
Gardiquimod (InvivoGen), R848 (InvivoGen), Sendai virus (Charles
River Laboratories), or Rift Valley fever virus for 24 h. Combined super-
natant and lysate samples were harvested for further analysis via enzyme-
linked immunosorbent assay (ELISA) and plaque assay unless otherwise
designated. For time course studies of IFN- and viral production, cells
were stimulated with RVFV NSs del at multiplicity of infection (MOI) of
1 for 2 h to allow for adsorption, after which the inoculum was removed
and replaced with medium. Supernatant was harvested at 6, 12, and 24 h,
and IFN- levels were determined by ELISA. The viral load in the super-
natant was determined via plaque assay.
FACS analysis of cell surface markers. The purity of bone marrow-
derived dendritic cells andmacrophages was confirmed with flow cytom-
etry. J558L-derived cDCs and FLT3L-derived mixed pDCs/cDCs were
stained with fluorochrome-linked antibodies for CD11c and CD11b
(eBioscience). The purity of macrophages was confirmed with F4/80 and
CD11b antibodies (eBioscience). Cells were incubated on ice for 15 min
with FBS to block Fc receptors and then with primary antibodies for 30
min on ice. Cells were fixed in 2% formaldehyde and were analyzed using
a BD LSRII flow cytometer and FlowJo software (Tree Star, Inc.).
Stimulation of transfected cell lines. HEK293XL cell lines stably ex-
pressing TLR7 and TLR8 were purchased from InvivoGen. A total of
40,000 cells were plated per well in a 96-well plate and transfected several
hours later using PolyJet (Signagen). HEK293XL cells and HEK293XL
cells stably transfected with TLR7 or TLR8 were transiently transfected
with a luciferase reporter plasmid for IFN- (promoter region) or NF-B
and constitutively active Renilla. The dominant-negative constructs
RIG-I Dn (RIG-I helicase domain) and MyD88 Dn (TIR domain only)
were transfected at the quantities described previously (30, 40). The total
DNA in each well was adjusted to 140 ng with pcDNA 3.1. The cells
were stimulated with media, RVFV, or control ligands Sendai (SV),
Gardiquimod (InvivoGen), R848 (InvivoGen), or 400 ng of poly(I·C)
(Amersham) transfected into cells with Lipofectamine 2000 (Invitrogen)
according to the manufacturer’s protocol for 18 h. Luminescence was
assessed using a Promega Glomax 96microplate luminometer. Luciferase
values were normalized to Renilla and a medium-only control.
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Western blotting. For Western blot analysis, 106 HEK293XL cells
were transfected using the following conditions: (i) untransfected cells,
(ii) pcDNA3.1, Renilla, and IFN- reporter plasmid, (iii) Renilla, IFN-
reporter, and dominant-negative construct, or (iv) dominant-negative
construct alone. The total amounts of DNA per transfection condition
were equal. Cell lysates were prepared in RIPA buffer with 1 mM dithio-
threitol (DTT) and a protease inhibitor cocktail (Thermo Scientific).
Samples were boiled for 5 min in Laemmli buffer. Protein samples were
subjected to SDS-PAGE using 4% bisacrylamide stacking and 15% bisac-
rylamide resolving gels. Proteins were transferred to polyvinylidene diflu-
oride (PVDF)membrane andwere blottedwith anti-Flag (Sigma) or anti-
AU-1 (Novus) in 4% nonfat driedmilk. Blots were stripped withWestern
blot stripping buffer (Thermo Scientific) and were reprobed with anti--
actin antibody A-15 (Santa Cruz).
Experimental infection of mice. For subcutaneous and intranasal
challenges of mice, the animals were infected with 3.5 103 or 3.5 104
PFU of RVFV rMP-12. Intranasal challenges were performed by admin-
istering 10 l of virus into the noses of anesthetized animals. Mortality
was recorded throughout the experiment. Surviving mice were weighed
daily (to 21 days), and all experiments were terminated on day 28.
To assess cytokine production, liver damage, and viral load through-
out infection, a separate study was conducted in which mice were ran-
domized based on sex and sacrificed on days 0, 2, 4, 6, 8, and 10 after
intranasal infections or when humane sacrifice was deemed necessary. At
the time of death, blood was collected using cardiac puncture, and serum
was isolated and used for assays. Livers and lungs were harvested and
homogenized in a 10% (wt/vol) solution of phosphate-buffered saline
(PBS).
Cytokine responses. A cell-free sample from 105 cells per well was
harvested and inactivated, and the cytokine levels were assessed using
ELISA. Sandwich ELISA for murine IFN- was performed as previously
described (41). Serum samples from WT and knockout (KO) mice were
analyzed for 32 cytokines simultaneously using a Milliplex array (Milli-
pore). The following cytokines and chemokines were measured: Eotaxin
(CCL11), granulocyte colony-stimulating factor (G-CSF), GM-CSF,
IFN-, interleukin-1 (IL-1), IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7,
IL-9, IL-10, IL-12p40, IL-12p70, IL-13, IL-15, IL-17, IFN--inducible
protein (IP)-10 (CXCL10), keratinocyte-derived chemokine (KC/
CXCL1), LIF, lipopolysaccharide (LPS)-induced chemokine (LIX/
CXCL5), MCP-1 (CCL2), M-CSF, mitogen-inducible gene (MIG/
CXCL9), MIP-1 (CCL3), MIP-1 (CCL4), MIP-2 (CXCL2), RANTES
(CCL5), tumor necrosis factor alpha (TNF-), and vascular endothelial
growth factor (VEGF). Samples that were out of range for LPS-induced
chemokine (LIX/CXCL5) from multiplex analysis were determined by
ELISA (R&D).
Plaque assay. Vero E6 cells were plated in 6- or 12-well plates 1 day
prior to infection. Viral dilutions were prepared in 1 MEM (Sigma
Chemicals) with sodium bicarbonate and 2% FBS (Atlanta Biologicals).
After 1 h of adsorption, viral dilutions were carefully removed and re-
placed with a 1:1 dilution of 1% agarose (Promega) and 2 MEM with
4% FBS. Infected cells were incubated for 3 days at 37°C, fixed with 10%
formaldehyde in PBS, and stained with 1% crystal violet–20% ethanol
solution. The plaques were counted, and the titer of the original sample
was determined.
Liver function test. Sera from WT and KO mice were assessed for
alanine transaminase (ALT) levels for each mouse on the day of harvest
using a color endpoint assay (Xpress Bio Life Science Products).
NanoString gene expression analysis. BMDMs or cDCs were plated
at 106 cells per well in six-well plates and then mock infected or infected
with rMP-12 or NSs del at MOIs of 1, 2, or 5 as indicated. Total RNA was
isolated at 6 h postinfection using an RNeasy minikit (Qiagen). A total of
100 ng of total RNA was hybridized to a custom mouse gene expression
CodeSet (consisting of a panel of inflammatory cytokines and IFN-stim-
ulated genes [ISGs]) and analyzed on annCounter digital analyzer (Nano-
String Technologies). Counts were normalized to internal spike-in and
endogenous housekeeping controls. The results from the NanoString ex-
periment were normalized according to the manufacturer’s protocol. A
pseudocount was added to all values, such that the smallest value in the
data set was equal to 1. All values were log transformed and, in the case of
data obtained with cDCs, a heat map was generated using the ggplot
package within the open source R software environment.
Statistical analysis. Data were analyzed using commercial software
(GraphPad). ELISA and cultured macrophage and DC virus load were
analyzed using a Student independent t test. Cytokine levels were assessed
by multiplex and ALT levels were analyzed by using a nonparametric
Mann-Whitney test. Comparison of survival curves was performed using
a log-rank test. P values are presented when statistical significance was
observed (significance was set at P 0.05).
RESULTS
RVFV-induced activation of IFN- is dependent on RIG-I. Pre-
viously, isolated RVFV RNAwas shown to activate an IFN- pro-
moter in HEK293T cells and was dependent on RIG-I and not on
MDA5 (31). To confirm whether whole RVFV particles can acti-
vate the IFN- promoter during the course of infection,
HEK293XL cells (transfected with a luciferase reporter construct
for IFN-) were stimulated with rMP-12 and NSs del strains at
MOIs of 1 and 5. We observed negligible activation of the IFN-
luciferase reporter by rMP-12, in contrast to the NSs del strain,
which produced strong induction of the IFN- reporter (Fig. 1A).
This was not unexpected, since rMP-12 expresses the virulence
factor NSs which has been shown by others to specifically inhibit
IFN- transcription (42). To determine whether activation was
RIG-I specific, HEK293XL cells were transiently cotransfected
with the IFN- reporter and increasing concentrations of an in-
hibitory plasmid RIG-I Dn (helicase domain only). We show that
inhibition of RIG-I resulted in a dose dependent reduction in
IFN- activation after stimulation with NSs del. This effect was
specific, since MDA5-driven IFN- activation by transfected
poly(I·C) was not affected by the addition of the RIG-I dominant-
negative construct, whereas RIG-I-mediated IFN- activation by
Sendai virus was reduced (Fig. 1B) (43). Expression of the RIG-I
Dn construct was confirmed by Western blotting (Fig. 1E).
RVFV-induced activation of IFN- is independent of endo-
somal TLRs. In order to determine whether TLRs contribute to
type I IFN promoter activation and production in response to
RVFV, HEK293XL cells stably overexpressing TLR7 or TLR8
were transfected with the IFN- luciferase reporter and then
infected with rMP12 or NSs del strains. As observed in
HEK293XL null cells (i.e., not transfected with TLRs), rMP-12
did not induce IFN- promoter activation (data not shown).
The NSs del strain induced IFN- promoter activation in TLR7
(Fig. 1C) and TLR8 (Fig. 1D) infected cells, but at a similar level
to the HEK293XL null cells. MyD88 is an adaptor molecule that
can be utilized by all TLRs except for TLR3 during signaling
(9). Activation of the IFN- reporter was not affected by the
addition of dominant-negative mutant MyD88 Dn (TIR do-
main only), suggesting that TLR7 and -8 do not contribute to
IFN- promoter activation by RVFV. As a control, the overex-
pression of MyD88 Dn did reduce the activation by
Gardiquimod in TLR7 cells (Fig. 1C) and by R848 in TLR8 cells
(Fig. 1D). The expression of theMyD88 Dn construct was dem-
onstrated by Western blotting (Fig. 1E).
Induction of type I IFN is dependent on MAVS signaling in
primary immune cells.Data from our transfection studies sug-
gest that RIG-I is an important mediator of type I IFN produc-
Ermler et al.
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tion in response to infectious RVFV. In order to determine
which innate immune receptors contribute to type I IFN pro-
duction in primary immune cells, bone marrow cells from WT
mice and mice lacking specific innate immune receptor and
adaptor proteins were differentiated into macrophages, cDCs,
or FLT3L-derived mixed pDCs/cDCs. Cells were stimulated
with RVFV strains rMP-12 and NSs del at a range of MOIs for
24 h. The absence of MAVS (common adaptor for RIG-I and
MDA5) led to a significant reduction in RVFV-induced type I
IFN production by cDCs (Fig. 2A) and macrophages (Fig. 2B).
This decrease was most notable in response to NSs del strain
but could also be observed with rMP-12 strain. The absence of
MAVS signaling also reduced IFN- levels to below the level of
detection when mixed pDCs/cDCs were stimulated with NSs
del at an MOI of 1 (Fig. 2C).
Although most of the type I IFN response was dependent on
RNA helicase signaling, this did not exclude the possibility that
TLRs could contribute to minor amounts of IFN in response to
FIG1 RVFV-induced IFN- responses are dependent on cytoplasmic RIG-I and are independent of TLRs. (A)HEK293XL cells were transfectedwith a luciferase
construct for the IFN- promoter and stimulated with medium only (M) or RVFV rMP-12 or NSs del strains at anMOI of 1 or 5 for 18 h. (B) IFN- activation
inHEK293XL cells transfectedwith 0, 10, 50, or 100 ng of RIG-I dominant-negative construct (RIG-IDn) and stimulatedwithmedium (M) orNSs del at anMOI
of 5 for 18 h. Cells were stimulated with control ligands Sendai virus (SV) and 400 ng of transfected poly(I·C) [Trans poly(I:C)] for 18 h with or without the
addition of RIG-I dominant-negative construct. (C and D) HEK293XL cells were stably transfected with TLR7 (C) or TLR8 (D) and transiently transfected with
MyD88 dominant-negative construct (MyD88Dn) at 0, 10, 50, or 100 ng. The cells were transfected with IFN- reporter construct and stimulated withmedium
(M) orNSs del strain at anMOI of 5. Controls were performed using theNF-B luciferase reporter and the TLR7-specific ligandGardiquimod (C) or the TLR7/8
ligand R848 (D) for 18 h. The data represent mean values	 the standard deviations based on triplicate wells from a representative experiment. Each experiment
was performed at least three times. Significance: ***, P 0.001; **, P 0.01. (E)Western blot confirming the expression of RIG-I Dn in HEK293XL cells and of
MyD88 Dn in TLR7 and TLR8 cells. The cells were either (i) not transfected, (ii) transfected with IFN- luciferase reporter, Renilla, and pcDNA 3.1 (plasmids),
(iii) transfected with the dominant-negative construct, reporter, and Renilla (MyD88 Dn plasmids), or (iv) the dominant-negative construct alone (MyD88 Dn).
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RVFV. The role ofMyD88was assessed in cDCs andmacrophages
using cells derived fromMyd88
/
mice thatwere stimulatedwith
virus for 24 h. The absence of MyD88 did not impact robust type
I IFN production in cDCs (Fig. 3A) or inmacrophages (Fig. 3B) in
response to RVFV rMP-12 or NSs del.
TLR3 can recognize dsRNA intermediates from viral replica-
tion and signal through adaptor molecule TRIF to lead to type I
IFN production (18, 44). Recent evidence suggests that the
amount of dsRNA intermediates generated by negative-strand
RNA viruses is negligible compared to the dsRNA intermediates
produced during positive-strand RNA viral replication (45). In
addition, TRIF or MyD88 can serve as an adaptor for TLR4
signaling (18). TLR4 has been shown to be involved in the recog-
nition of viral glycoproteins (46–48). BMDMs and cDCs were
generated from TLR3 and corresponding adaptor TRIF-deficient
mice and were infected with RVFV rMP-12 and NSs del for 24 h.
Neither the adaptor molecule TRIF nor the TLR3 contributed
significantly to type I IFN production in cDCs (Fig. 3C and E) or
macrophages (Fig. 3D and F). These studies demonstrate that
RVFV-induced type I IFN production is primarily dependent on
RNA helicase adaptor MAVS in immune cells and that TLR sig-
naling does not contribute to type I IFN responses.
The absence ofMAVS results in increased viral load in cDCs.
We hypothesized that RVFV-infected cells lacking robust type I
IFN responses would have an increased viral burden compared to
cells with competent IFN production. The total viral load (from
supernatant and lysate) was assessed in WT andMavs
/
macro-
phages or cDCs by using a plaque assay after 24 h of infection. As
expected, in correlation with reduced IFN responses after infec-
tion, cDCs from Mavs
/
 mice showed a significantly increased
viral burden when infected with RVFV rMP-12 (Fig. 4A) or NSs
del (Fig. 4B) compared to cDCs derived fromWTmice. Interest-
ingly, macrophages fromMavs
/
mice did not show a significant
difference in viral load after infection with either RVFV rMP-12
(Fig. 4C) orNSs del (Fig. 4D) compared toWTcells.Macrophages
derived from Myd88
/
 mice also did not have a significant dif-
ference in total viral load of rMP-12 or NSs del compared to WT
(Fig. 4E and F).
Although our findings show thatMAVS is crucial for type I IFN
response to RVFV at 24 h, we sought to determine whether other
receptors, including TLRs, could have an impact on IFN produc-
tion earlier during infection. cDCs were generated from WT and
Mavs
/
 orMyd88/Trif
/
mice (lacking all TLR signaling) and
were stimulated with rMP-12 and NSs del at an MOI of 1. IFN
responses were assessed at 6, 12, or 24 h. A significant decrease
in IFN- production in response to NSs del virus by cDCs from
Mavs
/
 compared to WT mice was detected at all of the mea-
sured time points (Fig. 5A). The absence of TLR signaling in
cDCs did not impact IFN- production at early or late time
points in response to rMP-12 (when detectable) or NSs del
compared to WT cells (Fig. 5B). We examined the degree to
which cDCs and macrophages could amplify RVFV over time.
Cells were infected with rMP-12 or NSs del at an MOI of 1, and
virus was removed after 2 h of adsorption to ensure viral load
measured in the supernatant at early time points was due to
productive infection versus lack of entry. Supernatants were
collected after 6, 12, or 24 h of infection, and the virus titers
were determined. Viral release was minimal in cDCs and mac-
FIG 2 IFN production in primary immune cells challenged with RVFV is dependent on MAVS. The dependence of type I IFN production on innate adaptor
molecule MAVS was assessed in cDCs (A), macrophages (B), and FLT3L-derived mixed pDCs and cDCs (C). IFN- levels were determined via ELISA from cell
samples harvested at 24 h. The data representmean values	 the standard deviations based on triplicate wells from a representative experiment. Each experiment
was performed at least three times. Significance: ***, P 0.001; **, P 0.01; not significant (NS), P 0.05. BLD, below the limit of detection.
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rophages, with no detectable difference between WT and
Mavs
/
 (Fig. 5C and E) or Myd88/Trif
/
 cDCs and macro-
phages (Fig. 5D and F).
Having established thatMAVS is a central regulator of the type
I IFN response to RVFV infection in macrophages and cDCs, we
next used a multiplex gene expression analysis platform (Nanos-
tring nCounter) to examine the role of MAVS in transcriptional
regulation of a panel of type I IFN-inducible genes in RVFV-in-
fected cells. BMDMs and cDCs from WT mice infected with the
rMP-12 strain showed upregulated expression of a panel of 42
genes that included Ifnb, Ifna4, and IFN-stimulated genes (ISGs)
such as Adar (adenosine deaminase, RNA-specific), Ddx58 (RIG-I),
Dhx58 (Lgp2), Rsad2 (Viperin), Stat1, Mndal (myeloid nuclear
differentiation antigen-like), and Ifi204 (Fig. 6A). Gene expres-
sion profiles in WT cDCs were compared after infection with
rMP-12 or NSs del virus and were normalized to mock-infected
controls. Gene expression in cDCs showed similar patterns of reg-
ulation in cells infected with either viral strain (Fig. 6B). We also
assessed the requirement for RNAhelicase signaling by comparing
gene expression betweenWT andMavs
/
 cells (Fig. 6C). Inmost
cases, the induction of these genes in response to RVFV was de-
pendent on MAVS. These observations suggest that MAVS is a
central regulator of the transcriptional response to RVFV infec-
tion in DCs.
MAVS is protective against mucosal challenge with RVFV in
mice. RVFV can infect humans and animals in a natural setting
throughmultiplemechanisms, such as bites frommosquitoes har-
boring the virus or through mucosal exposure to aerosols and
droplets (49). Infectious droplet and/or aerosol exposure can oc-
cur during the slaughter or processing of infected livestock or the
handling of aborted fetuses when pregnant animals become in-
fected (49). In order to compare the impact of route of infection
FIG 3 IFN- production not dependent on TLRs. The impact of TLR adaptor molecules MyD88 (A and B) and TRIF (C and D) or of TLR3 (E and F) on type
I IFNproductionwas determined in cDCs andmacrophages. The IFN- levels were determined via ELISA froma cell sample harvested at 24 h. The data represent
mean values	 the standard deviations based on triplicate wells from a representative experiment. Each experiment was performed at least three times. NS (not
significant), P 0.05. BLD, below the limit of detection.
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on mortality, mice were challenged either intranasally or subcu-
taneously to mimic these natural routes of exposure. C57BL/6
mice (7 to 9weeks of age)were infected via subcutaneous injection
or intranasal droplet with different doses of rMP-12. All mice
infected via either route with 3.5  103 PFU of virus survived
challenge. Mice infected with 3.5 104 PFU of virus intranasally
experienced higher mortality compared tomice infected subcuta-
neously with the same dose of rMP-12 (Fig. 7A). Therefore, dur-
ing subsequent in vivo challenges, 3.5  104 PFU of virus was
administered via the intranasal route.
Our in vitro studies have demonstrated a clear role for
MAVS and RIG-I in RVFV-induced type I IFN responses; how-
ever, the role of these molecules in clinical infection is unclear.
To determine the role of MAVS in susceptibility to RVFV in-
fection in vivo, intranasal inoculation with rMP-12 was per-
formed using WT and Mavs
/
 mice, and survival was moni-
tored for 28 days. After mucosal challenge, mice lacking MAVS
experienced significantly more mortality over time compared
to WT mice (Fig. 7B).
In order to determine whether MAVS had an impact on early
innate immune responses and morbidity, intranasally infected
WT and Mavs
/
mice were sacrificed in groups every other day
out to 10 days. Spontaneous death inMavs
/
mice began occur-
ring on day 5 of infection, whereas Mavs/ mice began to suc-
FIG 4 MAVS-dependent signaling controls viral load in cDCs. Bone marrow-derived cDCs and macrophages fromWT andMavs
/
mice were infected with
rMP-12 (A, C, and E) and NSs del (B, D, and F) at various MOIs. The total viral load was determined by plaque assay after 24 h of infection in cDCs (A and B)
andmacrophages (C, D, E, and F). (A toD) The data representmean values	 the standard deviations based on triplicate wells from a representative experiment.
Each experiment was performed at least three times. (E and F) The mean PFU is shown for an MOI of 1. The mean PFU	 the standard deviation is shown for
MOIs of 0.01 and 0.1 (n 2). Significance: *, P 0.05.
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cumb to infection on day 8. All euthanized mice underwent nec-
ropsy and were photographed. Mavs
/
mice sacrificed on day 8
had a pale ischemic liver and necrotic bowel compared to unin-
fected control mice (data not shown). We also noted that mice
requiring humane sacrifice deteriorated quickly, transitioning
from apparently healthy to moribund within a matter of hours.
No neurological symptoms in infectedmice were observed during
the course of infection.
Wild-type mice infected intranasally with RVFV rMP-12
had undetectable viral loads in the serum, liver, and lungs at
early (day 0 to 2), middle (day 4 to 6), and late (day 8 to 10)
time points during the study (Fig. 8A to C). In contrast, a subset
ofMavs
/
mice exhibited elevated viral loads in serum (Fig. 8A)
during the middle (days 4 to 6) to late (days 8 to 10) stages of
infection; however, themajority of themice hadundetectable viral
loads. Themean serum viral loads for the positivemice were 1.3
105 PFU/ml in themiddle period and 1.2 103 PFU/ml in the late
period.
Mavs
/
 mice also exhibited higher viral loads compared to
WTmice in the liver (Fig. 8B) during the middle to late periods of
infection. The mean liver titer during the middle period of
infection inMAVS-deficient mice was 8.5 105 PFU/g. During
the late period of infection, the mean virus titer was 6  102
PFU/g. In correlation with elevated viral loads in the liver,
Mavs
/
 mice exhibited elevated ALT levels, a marker for liver
damage, compared to WT mice with levels peaking during the
middle period of infection (days 4 to 6) (Fig. 8D).
Viral load was higher in the lungs of Mavs
/
 mice com-
pared toWTmice during the middle period of infection, with a
mean titer of 3.8 104 PFU/g in viremicmice (Fig. 8C). Similar
FIG 5 Time course of IFN responses to RVFV. Bone marrow-derived cDCs or macrophages from wild-type mice or MAVS- or MyD88/TRIF-deficient
mice were infected with rMP-12 or NSs del at an MOI of 1 for 6, 12, or 24 h. The IFN- responses of cDCs from wild-type mice (A and B) MAVS (A)- or
MyD88/TRIF (B)-deficient mice were measured by ELISA. The virus titer was determined in supernatant collected from infected cDCs (C and D) or
macrophages (E and F) by plaque assay. The mean levels of IFN- 	 the standard deviations from three experiments are shown. Significance: ***, P 
0.001; **, P  0.01; *, P  0.05.
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to WT mice, the MAVS-deficient mice showed undetectable
levels of virus in the lungs during the late period of infection.
Despite a deficiency in type I IFN and ISG production ob-
served in vitro, Mavs
/
mice exhibited a robust inflammatory
response throughout infection, as measured in serum collected
throughout infection (Table 1). Inmice humanely sacrificed on
day 5, cytokines with the overall highest induction in Mavs
/

mice included IL-6, G-CSF, and MIG (data not shown). Cyto-
kines IL-6, IL-10, MCP-1, and MIG were significantly in-
creased in Mavs
/
 mice compared to wild-type on day 8 of
infection (Table 1). Other cytokines that had a notable (4-
fold) induction in Mavs
/
 compared to WT mice included
GM-CSF, IFN-, IL-1, IL-2, IL-4, IL-12p70, IL-17, MIP-1,
MIP-1, and TNF-. Cytokines with 4-fold induction be-
FIG 6 MAVS-dependent gene expression induced by RVFV. (A)Multiplexed NanoString analysis was performed on BMDMs and cDCs 6 h after infection with
rMP-12 at an MOI of 1. The data are shown as the log10 fold change in infected cells compared to uninfected cells. (B) Normalized mRNA levels for a panel of
innate genes in WT cDCs infected for 6 h with rMP-12 or NSs del at an MOI of 2. (C) Innate gene responses of WT andMavs
/
 cDCs 6 h after infection with
rMP-12 at an MOI of 5. The data are shown as log-transformed normalized counts.
Ermler et al.
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tween WT and Mavs
/
 on day 8, when wild-type mice began
to succumb to infection, included Eotaxin, G-CSF, IL-1, IL-5,
IL-7, IL-9, IL-13, IL-15, IP-10, KC, LIF, LIX, M-CSF, MIP-2,
RANTES, and VEGF. The levels of IL-3 and IL-12p40 were
below the limit of detection in serum samples from both mouse
groups on day 8 (data not shown). Interestingly, of the 32
cytokines and chemokines tested, CXCL5 (LIX) was the only
protein measured that was higher in WTmice and decreased in
Mavs
/
 mice on all days measured (data not shown). LIX
protein levels tended to decrease inWT andMavs
/
mice over
time compared to uninfected mice.
RIG-I and MDA5 mediate type I IFN response through
MAVS adaptor molecule. After demonstrating a clear role for
MAVS in vitro and in vivo, we further delineated which upstream
receptors were recognizing RVFV and signaling through this
adaptor molecule. IFN- responses of cDCs generated from WT
and Rig-I
/
 and Mda5
/
 mice were measured after infection
with rMP-12 or NSs del for 6, 12, or 24 h. Negligible IFN- was
induced by rMP-12 in cDCs from WT, Rig-I 
/
, and Mda5
/

mice at all time points. A significant reduction in IFN- produc-
tion was observed in NSs del-infected cDCs from Rig
/
 mice
compared to WT mice at 12 and 24 h (Fig. 9A). cDCs from
Mda5
/
 mice also showed significantly reduced levels of IFN-
at 6 and 12 h compared to cDCs fromWTmice. However, by 24 h
the IFN- responses from Mda5
/
 cells were comparable to
those of the WT mice (Fig. 9B).
FIG 7 Survival following RVFV infection is dependent on the route of infection and MAVS. (A) Mice were infected either subcutaneously or intranasally and
weremonitored daily for death or severemorbidity (fivemice per group). (B)WT(n 12) orMavs
/
 (n 13)micewere challenged intranasally andmonitored
daily for 28 days. All infections were performed with 3.5 104 PFU of rMP-12. Significance: **, P 0.01.
FIG 8 Increased viral burden and organ damage in Mavs
/
mice compared to WT mice after mucosal RVFV exposure. The viral burden was determined by
plaque assay in serum (A), liver (B), and lung (C) inMavs
/
mice (Œ) compared toWTmice () during intranasal infectionwith 3.5 104 PFUof rMP-12/ml.
The dotted line signifies the lower limit of detection. (D) Serum ALT levels inMavs
/
mice (Œ) compared toWTmice (). Significance: *, P 0.05. ND, not
determined.
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DISCUSSION
The data presented here demonstrate for the first time that the
RNAhelicase adaptorMAVS is required for type I IFNproduction
in primary immune cells and is protective against mortality and
morbidity during live RVFV mucosal challenge. We show that
RIG-I is the predominant helicase responsible for type I IFN re-
sponses, although MDA5 may also play a role at the earliest time
points of viral entry. Our studies demonstrate that TLRs do not
play a role in RVFV induced type I IFN production, either in a
human cell line or in murine immune cells. This is an important
finding, since viruses can potentially enter the endosome after
binding to a receptor on the cell surface, and thus genomic mate-
rial could then be sensed by endogenous TLRs during infection
(28). Viral nucleic acid can also be taken up into the endosome
during autophagy (28), which would provide another potential
mechanism for endosomal receptor sensing.
Using in vitro reporter assays, we demonstrate that intact RIG-I
signaling is necessary for IFN- promoter activation by RVFV.
HEK293 cells are a useful model system for TLR activation since
the basal expression of most TLRs is negligible. Cells stably trans-
fected with TLR7 or TLR8 that have potential for the recognition
of single-stranded viral genomic RNA did not have enhanced
IFN- signaling compared to basal HEK293 cells, indicating that
the endosomal TLRs do not contribute substantively to IFN in-
duction by RVFV. The addition of a dominant-negative construct
targeting MyD88 (a common adaptor molecule for these recep-
tors) did not impact IFN- promoter activation, indicating that
TLR7 or TLR8 activation and signaling via MyD88 is dispensable
for RVFV-induced IFN-.
Initial studies performed in HEK293 cells to determine key
PRRs were confirmed using primary immune cells from WT and
genetically deficient mice. These studies reveal for the first time
important innate receptor recognition utilization bymacrophages
andDCs during RVFV infection. RNA cellular helicases were con-
firmed to be key receptors used by primary immune cells for rec-
ognition of RVFV, leading to the induction of type I IFN through-
out infection. We were surprised at the overall low level of IFN
produced by FLT3L-inducedDCs compared toGM-CSF-induced
cDCs or L929-derived macrophages, since pDCs have been
thought to be themain producers of type I IFN in response to viral
infection (50). Although pDCs are known to express RLRs, liter-
ature suggests that pDCs rely mainly on the TLR system for viral
sensing (51, 52). FLT3L induces a mixed population of cDCs and
pDCs; however, these cDCs may be functionally different from
cDCs induced by GM-CSF since these populations are known to
contain DC subsets that express different PRRs (53).
The RNA helicase adaptor molecule MAVS was necessary
for control of total viral load in conventional DCs at 24 h for
higher MOIs. It is likely that viral load was suppressed by IFN
generated through MAVS signaling. In contrast, lack of MAVS
signaling or MyD88-dependent TLR signaling did not alter vi-
TABLE 1 Serum cytokine responses at peak of rMP-12 RVFV infection
Cytokine or
chemokine
Avg level (pg/ml)	 SDa:
WTmice Mavs
/
mice
MIP-1 4	 8 264	 229 66.0
IL-2 3	 6 164	 260 54.7
MIP-1 39	 62 1,369	 1,673 35.1
MCP-1 25	 34 687	 539* 27.5
IL-17 3	 6 63	 90 21.0
GM-CSF 21	 36 368	 567 17.5
IL-10 18	 15 305	 296* 16.9
IL-1 5	 12 80	 91 16.0
IL-12p70 16	 24 253	 422 15.8
MIG 909	 912 11,091	 12,506* 12.2
TNF- 3	 7 30	 26 10.0
IL-4 4	 9 37	 65 9.3
IFN- 21	 31 193	 322 9.2
IL-6 31	 38 240	 227* 7.7
G-CSF 720	 760 2,775	 3,542 3.9
M-CSF 7	 9 26	 20 3.7
IL-13 413	 125 1,457	 754 3.5
IL-5 35	 20 91	 115 2.6
IL-7 13	 12 19	 6 1.5
IL-9 931	 528 1,401	 944 1.5
MIP-2 76	 92 108	 30 1.4
Eotaxin 882	 333 1,125	 287 1.3
RANTES 43	 29 55	 33 1.3
IP-10 938	 1,064 1,141	 412 1.2
IL-1 508	 332 536	 323 1.1
VEGF 7	 9 8	 13 1.1
IL-15 237	 295 244	 139 1.0
LIF 18	 25 17	 5 0.9
KC 93	 82 85	 54 0.9
LIX 13,676	 13,160 9,369	 4,434 0.7
a The average cytokine levels were measured in serum samples from infected animals in
Mavs
/
mice compared to wild-type mice on day 8., fold change inMavs
/
 cytokine
levels compared toWT cytokine levels; *, P 0.05.
FIG 9 Type I IFN production is mediated through both RIG-I andMDA5. cDCs fromwild-type or mice deficient in RIG-I (A) orMDA5 (B) were infected with
rMP-12 or NSs del at anMOI of 1 for 6, 12, or 24 h. IFN- levels in supernatants were measured by ELISA. All results are means	 the standard deviations (n
3). Significance: *, P 0.05.
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ral replication in macrophages under these same conditions.
This was an unexpected finding, since MAVS was shown to be
necessary for type I IFN production in primary immune cells,
including macrophages, and type I IFN is known to hinder
replication of other viruses. There are several reasons why this
discrepancy could occur. For example, our studies have shown
that cDCs produce higher levels of type I IFN compared to
macrophages, and a more robust IFN response may be needed
to have an effect on RVFV replication. It is also possible that
macrophages are utilizing other antiviral defenses besides type
I IFN, such as the generation of reactive oxygen species or nitric
oxide (NO), phagocytosis, or other inflammatory pathways.
For example, multiplexed analysis of gene regulation in rMP-
12-infected macrophages revealed that Nos2 (nitric oxide syn-
thase 2) was upregulated 44-fold compared to uninfected cells.
In comparison, GM-CSF-derived cDCs showed only 5-fold up-
regulation after infection (data not shown). Another explana-
tionmay be that the potential for viral entry may differ between
macrophages and cDCs due to differential expression of sur-
face receptors. Recently, DC-specific intercellular adhesion
molecule-3 grabbing non-integrin (DC-SIGN) was determined
to be a receptor used in RVFV cell entry (54). However, not all
cells that are infected with RVFV express DC-SIGN, suggesting
there may be other critical receptors for viral entry.
Time course studies demonstrate that both macrophages
and cDCs allow for very minimal viral amplification since sim-
ilar viral burdens in the cell supernatant were observed over
time. In these experiments, virus was removed after 2 h adsorp-
tion so that only virus released from productively infected cells
could be assessed in the supernatant. The shorter adsorption
time and analysis of only virus present in the supernatant ver-
sus the total viral load of cells may be why a difference in WT
and Mavs
/
 cDC viral burden could no longer be observed at
24 h for these studies.
We utilized two strains of attenuated RVFV for our in vitro
studies. The NSs del strain offers insight into which receptors
can be activated by the virus, since virulent and rMP-12 strains
of RVFV would normally suppress type I IFN responses due to
the ability of NSs protein to specifically inhibit this pathway
(42, 55–57). It is important to note that some type I IFN was
generated in response to the rMP-12 strain in primary immune
cells, indicating that the inhibition of the host response is not
complete.
Our studies are the first to demonstrate that MAVS is protec-
tive against mortality during in vivoRVFV infection.We observed
increased amounts of type I IFN protein and ISG mRNA in cells
fromWT compared toMavs
/
mice, confirming the critical role
for type I IFN in RVFV infection. It had previously been estab-
lished that Ifnar
/
mice have more rapidmortality with virulent
RVFV strain ZH548 compared toWTmice. Also, Ifnar
/
mice
succumbed to infectionwithMP-12 and clone 13 strain infections
compared to nomortality observedwithWTmice inoculatedwith
those strains (8). We show that MAVS-deficient mice have in-
creased viral burden and more liver damage, as assessed by the
ALT level after in vivo challenge. It is interesting that even theWT
mouse requiring humane sacrifice on day 8 had a lower ALT level
compared to nonmoribundMavs
/
mice sacrificed at this time.
High mortality in Mavs
/
 mice after intranasal challenge with
rMP-12 was expected because of the deficit seen in the IFN pro-
duction of immune cells from these mice in vitro and supports
previously published studies showing high mortality in Ifnar
/

mice (8). Although this group reported a lack of virulence in WT
mice infected intraperitoneally with MP-12, we observed 50%
mortality with intranasal administration of rMP-12 in WT mice
(Fig. 7A). We have observed that the route of infection largely
impacts virulence, with significantly less virulence observed with
subcutaneous challenge than with intranasal challenge (Fig. 7A).
This may be due to a difference in which cells and organs first
come into contact with the virus based on the route of virus
introduction, leading to different profiles or magnitudes of
host inflammatory responses. Further studies, beyond the
scope of the present study, may also show a differential suscep-
tibility in animal models challenged with virulent RVFV de-
pending on the route of exposure. This could have potential
implications for human RVFV infections, wherein a range of
clinical severity and symptoms have been observed, and where
risk factors for infection include both mosquito and mucosal
routes of exposure (49, 58).
Interestingly, in vivo, a variety of inflammatory cytokine re-
sponses were not hindered in the absence of MAVS signaling.
Many of the Mavs
/
 mice that were humanely sacrificed due to
moribund appearance exhibited a cytokine storm. The inflamma-
tory proteins abundant in overwhelming amounts on day 5 in two
mice requiring humane sacrifice included IL-6, G-CSF, and MIG
(data not shown). IL-6 is known to be fever inducing and has been
shown to be associated with other hemorrhagic fever virus infec-
tions (59, 60). G-CSF has many functions, including reducing
cellular apoptosis and quelling inflammation associatedwith neu-
rodegenerative diseases (61). G-CSF has also been shown to pro-
mote the accumulation of Ly6G granulocytes during influenza
virus or Sendai virus infection to aid in viral clearance and main-
tain survival (62). MIG (CXCL9) has been shown to reduce coro-
navirus-induced liver and brain pathology (63). The cytokines
IL-10 andMCP-1were shown to be significantly different between
WT andMAVS-deficient mice. IL-10 is known to be an immuno-
modulator and can inhibit antigen presentation and the produc-
tion of inflammatory cytokines (64). IL-10 has been shown to
decrease inflammation and liver damage without altering viral
load in amodel ofmurine cytomegalovirus infection (65).MCP-1
alters the migration of monocytes and macrophages that are im-
portant for combating viral infection (66).
RLRs upstream of MAVS are important for type I IFN pro-
duction in response to RVFV infection. As expected, the ab-
sence of RIG-I significantly reduced IFN- production by
cDCs when infected with NSs del, strengthening our findings
from in vitro studies using HEK cells in which RIG-I Dn nega-
tively impacted activation of the IFN- promoter. In bone
marrow-derived cDCs, MDA5 also appeared to influence early
IFN- production in response to RVFV, which likely accounts
for the residual responses seen in the Rig-I
/
 cells at 24 h.
Rig-I and Mda5 genes were similarly activated during rMP-12
and NSs del infection of WT cDCs. RIG-I andMDA5 recognize
different viral nucleic acid patterns; RIG-I recognizes the 5=
triphosphate end of ssRNA generated by viral polymerases,
whereas MDA5 recognizes dsRNA and has been shown to be
critical for recognizing members of the picornavirus family
(43). Despite recognizing distinct substrates, both RIG-I and
MDA5 have also been shown to contribute to recognition of
West Nile virus and dengue virus (67, 68). Here, we also dem-
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onstrate a redundant role for these molecules in the induction
of type I IFN responses by RVFV.
Although these studies have identified the initial receptor
dependence in IFN production in mice, receptor preference in
human cells should be verified. In a clinical setting, RVFV-
infected patients exhibit a wide range of symptoms, from mi-
nor febrile illness to much more severe manifestations such as
hemorrhagic fever and death. It is unknown why such a range
of variability exists between patients. It is likely that genetic
factors may contribute to this diversity. Studies with rats have
confirmed that resistance against severe RVFV-induced pa-
thology can be inherited as a dominant gene (69) and that
subtle differences between rats of the same strain from differ-
ent facilities can alter disease outcomes (70, 71). Ultimately,
polymorphisms in crucial innate immune receptors in human
populations could be identified and screened in conjunction
with monitoring the gamut of patient disease progression.
Polymorphisms in receptors that bolster early and robust type
I IFN responses could hold the key to unlocking the source of
diversity between severe and mild clinical outcomes in patients
infected with Rift Valley fever virus.
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